Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
L19TNF + lomustine dose optimization in recurrent glioblastoma
2024-515609-25-00Phase 2Withdrawn
- Sponsor
- Philogen
- Start
- Dec 2024
- Modality
- Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes, Antibody Fragments → Engineered Antibody Formats → Antibody-Based Therapeutics, Cytokines & Interferons → Recombinant Proteins and Enzymes
- Countries
- 4
01
Overview
Phase 2, single-arm trial of onfekafusp alfa in glioblastoma (GBM), sponsored by Philogen. Primary endpoints: Safety - Incidence of adverse events and Survival rate at 12 months. Planned start Dec 2024; status: withdrawn.
02
Drugs
onfekafusp alfa
03
Conditions
glioblastoma (GBM)
Beyond the preview
Go deeper on 2024-515609-25-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-515609-25-00.